Literature DB >> 19652650

Paget disease: when to treat and when not to treat.

Frederick R Singer1.   

Abstract

Paget disease of bone is a focal disorder of the skeleton that can affect one or more bones. Many patients are discovered accidentally because of elevated serum alkaline phosphatase activity or an abnormal skeletal radiograph intended to evaluate an unrelated condition. Patients are often asymptomatic, but a subset experience considerable morbidity that can include bone pain and skeletal deformity, as well as a variety of regional complications, such as hearing loss associated with cranial involvement, degenerative arthritis of the hip or knee, fractures of the lower extremities and, rarely, sarcoma or giant cell tumors. Bisphosphonates have proven to be effective in controlling disease activity because they inhibit osteoclast function. Administration of these agents can relieve bone pain, decrease biochemical markers of bone resorption and bone formation, and retard or reverse the early osteolytic phase of the disease. Future studies are needed to determine whether these drugs, if used in an early stage of the disease, can prevent complications in asymptomatic patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652650     DOI: 10.1038/nrrheum.2009.149

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  68 in total

Review 1.  [Italian guidelines for the diagnosis and treatment of Paget's disease of bone].

Authors:  S Adami; P Bartolozzi; M L Brandi; A Falchetti; P Filipponi; S Gonnelli; G Bianchi; G C Isaia; R Nuti
Journal:  Reumatismo       Date:  2007 Apr-Jun

2.  Progression in length and width of pagetic lesions, and estimation of age at disease onset.

Authors:  J C Renier; M Audran
Journal:  Rev Rhum Engl Ed       Date:  1997-01

3.  Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

Authors:  E Siris; R S Weinstein; R Altman; J M Conte; M Favus; A Lombardi; K Lyles; H McIlwain; W A Murphy; C Reda; R Rude; M Seton; R Tiegs; D Thompson; J R Tucci; A J Yates; M Zimering
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

4.  Effects of mithramycin on Paget's disease of bone.

Authors:  W G Ryan; T B Schwartz; C P Perlia
Journal:  Ann Intern Med       Date:  1969-03       Impact factor: 25.391

5.  Association of Paget's disease of bone with calcific aortic valve disease.

Authors:  S A Strickberger; S P Schulman; G M Hutchins
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

6.  Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.

Authors:  David Hosking; Kenneth Lyles; Jacques P Brown; William D Fraser; Paul Miller; Manuel Diaz Curiel; Jean-Pierre Devogelaer; Michael Hooper; Guoqin Su; Ken Zelenakas; Judy Pak; Taiwo Fashola; Youssef Saidi; Erik Fink Eriksen; Ian R Reid
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

Review 7.  Dynamic radiologic patterns of Paget's disease of bone.

Authors:  B Maldague; J Malghem
Journal:  Clin Orthop Relat Res       Date:  1987-04       Impact factor: 4.176

8.  A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

Authors:  D Thiébaud; P Jaeger; C Gobelet; A F Jacquet; P Burckhardt
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

Review 9.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone.

Authors:  R D Altman
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

View more
  10 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.

Authors:  Masaya Ohara; Yasuo Imanishi; Yuki Nagata; Akira Ishii; Ikue Kobayashi; Katsuhito Mori; Manabu Ito; Takami Miki; Yoshiki Nishizawa; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2014-10-16       Impact factor: 2.626

Review 3.  Disorders of bone remodeling.

Authors:  Xu Feng; Jay M McDonald
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

4.  Osteosclerosis owing to Notch gain of function is solely Rbpj-dependent.

Authors:  Jianning Tao; Shan Chen; Tao Yang; Brian Dawson; Elda Munivez; Terry Bertin; Brendan Lee
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

Review 5.  Emerging strategies and therapies for treatment of Paget's disease of bone.

Authors:  Laëtitia Michou; Jacques P Brown
Journal:  Drug Des Devel Ther       Date:  2011-04-26       Impact factor: 4.162

6.  Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.

Authors:  Bruno Ferraz-de-Souza; Regina M Martin; Pedro Henrique S Correa
Journal:  J Bone Miner Metab       Date:  2012-10-18       Impact factor: 2.626

Review 7.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

Review 8.  Tissue Engineering Through 3D Bioprinting to Recreate and Study Bone Disease.

Authors:  Adriene Pavek; Christopher Nartker; Maamoon Saleh; Matthew Kirkham; Sana Khajeh Pour; Ali Aghazadeh-Habashi; Jared J Barrott
Journal:  Biomedicines       Date:  2021-05-14

9.  Clinical role of bisphosphonate therapy.

Authors:  Geeta Hampson; Ignac Fogelman
Journal:  Int J Womens Health       Date:  2012-09-03

10.  An injectable self-adaptive polymer as a drug carrier for the treatment of nontraumatic early-stage osteonecrosis of the femoral head.

Authors:  Ning Kong; Hang Yang; Run Tian; Guanzhi Liu; Yiyang Li; Huanshuai Guan; Qilu Wei; Xueshan Du; Yutian Lei; Zhe Li; Ruomu Cao; Yiwei Zhao; Xiaohui Wang; Kunzheng Wang; Pei Yang
Journal:  Bone Res       Date:  2022-03-12       Impact factor: 13.567

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.